Status:

COMPLETED

Extended-Release RANCAD in the Patients With Stable Angina Pectoris

Lead Sponsor:

TSH Biopharm Corporation Limited

Conditions:

Stable Angina Pectoris

Eligibility:

All Genders

20+ years

Phase:

PHASE3

Brief Summary

A double-blind, randomized, placebo-controlled, parallel study to evaluate the effects of add-on RANCAD on exercise tolerance and angina frequency in patients with stable angina pectoris.

Detailed Description

Primary objective is to to determine the effects of add-on RANCAD on exercise treadmill test (ETT) duration at trough plasma level of RANCAD level after 12-weeks therapy.

Eligibility Criteria

Inclusion

  • Male or female patients aged ≥ 20 years old
  • A minimum 3-month history of stable angina
  • Patients with diagnosis of coronary artery disease (CAD)
  • Patients present with the symptoms of stable angina after withdrawn from other antianginal drugs and given the required background therapy for at least 7 days will be qualified for entering this study and performing 1st ETT qualifying test
  • Patients developed exercise-induced ECG ischemiai during two qualifying exercise treadmill testsii. The difference between twoiii tests should be ≤ 20% of the longer test or ≤ 1 minute i. Exercise-induced ECG ischemia is defined as the new development of horizontal or down-sloping ST-segment depression of ≥1mm at 60-80ms after the J point; if patients with baseline ST depression at rest (\<1mm), qualifying ST segment depression is defined as additional ST depression of at least 1 mm below the resting value ii. Exercise treadmill test (ETT) will be performed by Modified Bruce Protocol. iii. Two qualifying tests will be conducted 1 week apart, a 3rd ETT test will be performed ≤ 3 days when differences between previous two qualifying ETTs \>20% of the longer test or \>1 minute
  • Willing and able to provide a written informed consent

Exclusion

  • Factors that might compromise ECG or ETT interpretation
  • Patients with resting ST-segment depression ≥ 1mm in any lead
  • Left bundle-branch block
  • Patients implanted with pacemaker
  • Patients under Digitalis therapy
  • Patients with family history of (or congenital) long QT syndrome
  • Patients with congenital heart disease
  • Patients with uncorrected valvular heart disease
  • Patients with unstable angina, or MI, or coronary revascularization procedure ≤ 2 months prior enter this study
  • Female who is pregnant/lactating or planning to be pregnant, or female of childbearing potential\* who is not using medically recognized method of contraception
  • \*Other than those who have been surgically sterilized (defined as having undergone hysterectomy or bilateral oophorectomy or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal.
  • Patients are under any one of the following conditions:
  • New York Heart Association (NYHA) Class III or Class IV congestive heart failure (CHF)
  • QTc \> 450 msec at screening
  • Active myocarditis, pericarditis, hypertrophic cardiomyopathy
  • Uncontrolled hypertension (defined as SBP \> 180 mmHg) Voltage criteria for left ventricular hypertrophy in the absence of repolarization abnormalities will not be exclusion criteria
  • Use of any investigational product ≤ 4 weeks prior to screening
  • Patients with severe hepatic disease (e.g., liver cirrhosis)
  • Patients with impaired renal function (defined as serum Cr \>1.5 mg/dl)
  • Patients with any condition or disease which is considered not suitable for this study by investigator

Key Trial Info

Start Date :

October 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2016

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT02294942

Start Date

October 1 2014

End Date

December 1 2016

Last Update

April 28 2017

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Far Eastern Memorial Hospital

New Taipei City, New Taipei city, Taiwan, 220

2

Mackay Memorial Hospital

Taipei, Taipei City, Taiwan, 104

3

Shin Kong WuHoSu Memorial Hospital

Taipei, Taiwan, 111

4

National Taiwan University Hospital

Taipei, Taiwan

Extended-Release RANCAD in the Patients With Stable Angina Pectoris | DecenTrialz